Precigen Regains Exclusive Rights to Proven CAR-T Targets, CD19 and BCMA, to Enable Unencumbered Development and Commercialization of UltraCAR-T®

Posted on by

– Precigen amends exclusive license agreement with Alaunos to bolster portfolio and broaden strategic opportunities – – The Company also regains exclusive rights to IL-12 gene therapy, including application through the AdenoVerse™ platform – Agreement eliminates all future royalties to…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.